早上好 感谢大家参加时代天使的2024年全业绩发布会我是高盛的分析师ChrisThis call has simultaneous English translationand if you are English speakeryou can switch to the English channel in Zoom公司的业绩昨天已经挂网我们今天也很荣幸请到了管理层来跟我们分享一下20年的总结和对25年的展望首先我先介绍一下出席今天的管理层包括董事会主席冯黛先生 执行董事兼首席执行官和首席技术官吴捷当先生执行董事兼国际业务总裁王坤先生执行董事兼首席运营官宋鑫先生执行董事兼首席财务官董立女士高级副总裁兼董事会秘书朱铃波先生 在我们开始之前请允许我先念一段免责声明此电话会为非公开的电话会仅开放高盛和时代天使的客户参加 谢绝媒体播录如果您不是高盛或者时代天使的客户或者稍微收到加入此电话的邀请则应立即挂断电话请注意高盛里面必须能够确认此会议的所有参与者 明年的身份您可能会被从会议中移除此电话的目的不是为了分享或接收非公开或其他机密信息与会者是二级市场的参与者他们不应获得有关发行人证券或证券市场的非公开或其他机密信息 ...

Group 1 - The core viewpoint of the articles is that Times Angel has launched an innovative children's anti-caries invisible orthodontic appliance, addressing both dental health and alignment issues for children aged 6-12 [1][2] - The product combines preventive care for cavities with orthodontic functions, filling a market gap and meeting the urgent needs of parents for comprehensive oral health management [1][2] - The launch of the anti-caries appliance has received widespread acclaim, with pilot programs established in over 20 provinces and municipalities across China since the beginning of the year [1] Group 2 - According to research by Zhaoshang Consulting, the compound annual growth rate (CAGR) of children's invisible orthodontic cases in China from 2020 to 2023 exceeds 60%, indicating significant market potential [2] - Compared to the penetration rate of orthodontic treatment among children and adolescents in the United States, China's rate remains low, suggesting ample growth opportunities in the market [2] - Times Angel advocates for a "scientific early orthodontics" approach and has developed a comprehensive product matrix to meet various orthodontic needs throughout different stages of childhood [2]

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of HK$103.50, indicating an expected relative performance above the market benchmark [2][5]. Core Insights - The company achieved a total of 359,000 cases of invisible orthodontics in 2024, representing a growth of 46.7%. International cases surged to 141,000, up 326.4%, accounting for 39.1% of total cases, while domestic cases grew by 3.2% to 218,000 [3][11]. - Revenue for 2024 reached US$270 million, reflecting a year-on-year increase of 28.2%, with a gross profit margin of 62.6%. The overseas revenue was US$80.5 million, a significant increase of 290.4%, while domestic revenue slightly declined by 0.4% to US$190 million [12][13]. - The company plans to establish a manufacturing facility in Wisconsin, USA, to enhance local operational capabilities, which is expected to reduce geopolitical risks and improve brand recognition among overseas orthodontists [14]. Financial Performance and Forecast - The company forecasts revenues of US$320 million and US$390 million for 2025 and 2026, respectively, with year-on-year growth rates of 19.4% and 20.1%. The net profit attributable to shareholders is expected to be US$12.4 million and US$13.3 million for the same years, reflecting growth of 2.3% and 7.6% [5][15]. - The adjusted net profit for 2024 was US$26.86 million, with a net profit margin of 10.0%. The domestic net profit margin was stable at 19.5%, while overseas losses narrowed slightly to US$29.65 million [13][4].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% against the market benchmark within the next six months [18]. Core Insights - The company achieved a revenue of $269 million in 2024, representing a year-on-year growth of 28.2%, and a net profit attributable to shareholders of $12 million, up 60.9% [2][4]. - The number of cases handled reached 359,400, marking a significant increase of 46.7% [2][4]. - The international expansion strategy is proving effective, with overseas case numbers soaring by 326.4% to 140,700, accounting for 39.1% of total cases, and overseas revenue increasing by 290.4% to $8.1 million, representing 30% of total revenue [4][5]. Financial Performance - The domestic market showed stable growth, with 218,700 cases (+3.2%) and revenue of $188 million (-0.4%), while the adjusted net profit remained stable at $37 million (+0.1%) [5]. - The overall gross margin improved to 62.6%, with a net margin of 3.7% and an adjusted net margin of 10.0% [6]. - The company is expected to see revenue growth projections for 2025-2027 at RMB 2.35 billion, RMB 2.72 billion, and RMB 3.22 billion respectively, with net profits projected at RMB 151 million, RMB 282 million, and RMB 385 million [6][7].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% within the next six months [20]. Core Insights - The company achieved a revenue of $269 million in 2024, representing a year-on-year growth of 28.2%, and a net profit of $12 million, which is a 60.9% increase [2][4]. - The number of cases handled reached 359,400, marking a significant increase of 46.7% [2][4]. - The international expansion strategy is proving effective, with overseas case numbers soaring by 326.4% to 140,700, accounting for 39.1% of total cases [4][5]. - The overseas revenue reached $8.1 million, a remarkable increase of 290.4%, contributing to 30% of total revenue [4][5]. Financial Performance - The overall gross margin for 2024 was 62.6%, with a net profit margin of 3.7%, both showing slight improvements year-on-year [6]. - The adjusted net profit margin was 10.0%, reflecting a decrease of 2.1 percentage points [6]. - The company’s domestic business maintained a steady growth, with domestic case numbers increasing by 3.2% to 218,700, while domestic revenue slightly declined by 0.4% to $188 million [5][6]. Future Projections - Revenue forecasts for 2025-2027 have been revised upwards, with expected revenues of 2.35 billion, 2.72 billion, and 3.22 billion RMB respectively [6]. - The projected net profits for the same period are 151 million, 282 million, and 385 million RMB, with corresponding P/E ratios of 63, 34, and 25 [6][7].

Summary of Angelalign Technology Inc Conference Call Company Overview - **Company**: Angelalign Technology Inc (6699.HK) - **Industry**: China Healthcare - **Current Stock Price**: HK$63.85 (as of March 21, 2025) - **Price Target**: Raised from HK$72.00 to HK$74.00 [2][4] Key Financial Updates - **Revenue Forecasts**: Increased by 5% for 2025, 7% for 2026, and 8% for 2027, driven by higher overseas growth [3][4] - **EPS Estimates**: Adjusted to -5% for 2025, +9% for 2026, and +12% for 2027 on a constant currency basis [3] - **GPM and OPM**: Lowered assumptions due to longer ramp-up times for new facilities in the US and Brazil [3] - **DCF Model**: Extended to 2035 with WACC reduced from 13% to 11% due to lower supply chain risks [4] Market Position and Growth Potential - **Market Share**: Angelalign holds over 40% case volume share in the clear aligner market, surpassing Invisalign since 2021 [11] - **Overseas Expansion**: Initiated in 2023-24, with significant growth potential from low existing market share [11] - **Supply Chain Diversification**: Initiatives in place to mitigate tariff risks, although breakeven may be delayed [11] Investment Thesis - **Valuation**: Despite high near-term P/E ratios reflecting expected overseas losses in 2025-26, the valuation remains attractive [12] - **Revenue Growth**: Anticipated strong near-term revenue growth due to industry demand recovery and market share gains in China [10] - **Risk Factors**: Potential risks include market share loss, rising competition, and delays in overseas ramp-up [23] Earnings Inputs - **China Case Shipment Volume**: Expected to grow from 218,700 in 2024 to 248,963.6 in 2027 [18] - **Overseas Case Shipment Volume**: Projected to increase from 140,700 in 2024 to 370,392.8 in 2027 [18] - **Selling Cost Ratio**: Expected to decrease from 39.1% in 2024 to 30.5% in 2027 [18] Consensus and Ratings - **Stock Rating**: Equal-weight [5] - **Industry View**: Attractive [5] - **Consensus Price Target Distribution**: Ranges from HK$64.07 to HK$103.38 [9] Conclusion Angelalign Technology Inc is positioned for growth with a strong market share in the clear aligner sector and significant overseas expansion potential. Despite some risks associated with competition and operational ramp-up, the company's financial outlook remains positive with revised revenue forecasts and a slightly increased price target.

Investment Rating - The report maintains a "Buy" rating for the company, anticipating a price increase of over 15% within the next 6-12 months [4][13]. Core Viewpoints - The company achieved a revenue of $26.9 million in 2024, reflecting a year-on-year growth of 28%, while the adjusted net profit was $26.9 million, up 3% [1]. - The international market outside of China has become a significant growth driver, with a 326.4% increase in invisible orthodontic cases and a revenue increase of 290.4% in 2024 [2]. - The company is strategically expanding its sales team in the domestic market, achieving a 3.2% increase in cases, although revenue in China slightly declined by 0.4% [2]. - The gross margin improved to 62.6%, with sales and marketing expenses rising by 49.9% due to international expansion efforts [3]. - The company is expected to continue its growth trajectory, with projected net profits of $1.06 billion, $1.28 billion, and $1.54 billion for 2024-2026, representing growth rates of 21%, 21%, and 20% respectively [4]. Summary by Sections Performance Review - In 2024, the company reported a revenue of $26.9 million, a 28% increase year-on-year, and an adjusted net profit of $26.9 million, up 3% [1]. Operational Analysis - The total number of cases reached 359,400 in 2024, a 47% increase year-on-year, with significant growth in international markets [2]. - The company recorded 140,700 cases outside of China, marking a 326.4% increase, and generated $80.5 million in revenue from these markets, a 290.4% increase [2]. - In the domestic market, the company achieved 218,700 cases, a 3.2% increase, but revenue slightly decreased by 0.4% to $188.2 million [2]. Profitability and Expenses - The gross margin for 2024 was 62.6%, an increase of 0.2 percentage points year-on-year [3]. - Sales and marketing expenses rose to approximately $105 million, a 49.9% increase, primarily due to the expansion of international operations [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of $1.06 billion, $1.28 billion, and $1.54 billion for 2024-2026, with corresponding EPS of 0.62, 0.75, and 0.90 [4]. - The current price-to-earnings ratio is projected to be 114, 95, and 79 for the years 2024-2026 [4].

RSU Grant and Vesting - The company announced the grant of 72,975 restricted stock units (RSUs) to 50 employees, equivalent to 72,975 shares of common stock, as part of its post-IPO restricted stock unit plan[3]. - The RSUs will vest in four tranches: 30% on September 30, 2025, 30% on September 30, 2026, 20% on September 30, 2027, and 20% on September 30, 2028[9]. - The total number of shares available for future grants under the post-IPO restricted stock unit plan is capped at 3,381,955 shares, with 1,478,931 shares available for future grants as of the announcement date[15]. - The RSUs granted do not have any performance targets attached to them[11]. - The purchase price for the shares on the RSU grant date is set at HKD 63.85 per share[9]. - The vesting schedule allows for some RSUs to have a vesting period of less than 12 months, subject to board discretion[9]. - The company has established mechanisms to ensure that unvested RSUs will be forfeited under certain conditions, such as termination of employment or misconduct[12]. Employee Motivation and Alignment - The company aims to recognize the contributions of RSU recipients and align their interests with those of shareholders to maximize employee motivation[14]. - The board believes that granting RSUs is an important measure to incentivize recipients to deliver higher returns for the company[14]. Financial Performance - The company's gross profit increased by 28.7% from approximately $130.7 million for the year ended December 31, 2023, to approximately $168.2 million for the year ended December 31, 2024[16]. - The gross profit margin for the year ended December 31, 2024, was approximately 62.6%[16].

Financial Performance - Revenue rose by 28.2% to approximately $268.8 million for the year ending December 31, 2024, up from about $209.6 million for the year ending December 31, 2023[4] - Gross profit increased by 28.7% to approximately $168.2 million for the year ending December 31, 2024, with a gross margin of approximately 62.6%[5] - Net profit grew by 46.6% to approximately $10.0 million for the year ending December 31, 2024, compared to about $6.8 million for the year ending December 31, 2023[5] - Revenue from markets outside of China surged by 290.4% to approximately $80.5 million for the year ending December 31, 2024, accounting for 30.0% of total revenue[4] - The adjusted net profit for the year ending December 31, 2024, was approximately $26.9 million, compared to about $26.1 million for the year ending December 31, 2023[5] - The company's revenue for the year ended December 31, 2024, was $268.79 million, an increase from $209.62 million in 2023, representing a growth of approximately 28.2%[58] - The gross profit margin improved to 62.6% in 2024 from 62.4% in 2023, while the net profit margin increased to 3.7% from 3.3%[50] - Adjusted net profit for 2024 was $26.86 million, compared to $26.11 million in 2023, reflecting a year-over-year increase of about 2.9%[56] - The company reported an adjusted EBITDA of $37.74 million for 2024, up from $26.26 million in 2023, indicating a growth of approximately 43.8%[56] Operational Highlights - The total number of completed cases for invisible orthodontics increased by 46.7% to approximately 359,400 cases for the year ending December 31, 2024, compared to about 245,000 cases for the year ending December 31, 2023[4] - The number of completed cases in markets outside of China increased by 326.4% to approximately 140,700 cases for the year ending December 31, 2024[4] - The company has adopted a strategy of "global organization + localized operation," expanding its business presence in over 50 countries[6] - The company launched the "Angel Aligner Education" app and received recognition for its innovative technology at major orthodontic conferences[8] - The launch of the "KiD Max" and "KiD防齲版" product lines expands the children's product matrix, addressing oral health issues for children and adolescents[11] Expenses and Investments - R&D investment reached approximately $21.3 million in 2024, accounting for 7.9% of total revenue[12] - Cost increased by 27.4% from approximately $78.9 million for the year ended December 31, 2023, to approximately $100.6 million for the year ended December 31, 2024, primarily due to global business expansion[20] - Sales and marketing expenses increased by 49.9% from approximately $70.1 million for the year ended December 31, 2023, to approximately $105.0 million for the year ending December 31, 2024, primarily due to global business expansion outside of China[22] - Administrative expenses rose by 16.2% from approximately $39.8 million for the year ended December 31, 2023, to approximately $46.2 million for the year ending December 31, 2024, reflecting improved operational efficiency as the growth rate was lower than revenue growth[23] - Research and development expenses decreased from approximately $24.6 million for the year ended December 31, 2023, to approximately $21.3 million for the year ending December 31, 2024[24] Cash Flow and Financial Position - Cash and cash equivalents and term deposits totaled approximately $339.1 million as of December 31, 2024, down from approximately $379.7 million as of December 31, 2023[34] - The current ratio decreased to 3.8 in 2024 from 4.2 in 2023, indicating a slight decline in liquidity[50] - The company reported a net financial income of $5.46 million for 2024, down from $12.44 million in 2023, reflecting a decrease of approximately 56.1%[58] - The total comprehensive income for the year ended December 31, 2024, was $3.95 million, compared to $4.21 million in 2023, showing a decline of about 6.4%[59] - Total liabilities rose to $197.87 million in 2024, up from $190.47 million in 2023, an increase of 3.67%[62] - The company reported a net cash outflow from financing activities of $28.46 million in 2024, compared to $26.31 million in 2023[66] Shareholder Information - The company plans to pay a special final dividend of HKD 0.38 per share for the year ending December 31, 2024[5] - The annual general meeting is scheduled for May 23, 2025, to discuss various corporate matters including the proposed dividend[131] - A special final dividend eligibility period will also see share registration suspended from May 29 to June 2, 2025[133] - The company expresses gratitude to oral doctors, patients, business partners, employees, and shareholders for their continued support and dedication[142] Corporate Governance and Compliance - The company has adopted corporate governance practices in compliance with the relevant codes and regulations[127] - The audit committee, consisting of three independent non-executive directors, has reviewed the group's annual performance for the year ending December 31, 2024, and recommended approval to the board[135]

Financial Performance - Revenue rose by 28.2% to approximately $268.8 million for the year ending December 31, 2024, up from approximately $209.6 million for the year ending December 31, 2023[4] - Gross profit increased by 28.7% to approximately $168.2 million for the year ending December 31, 2024, with a gross margin of approximately 62.6%[4] - Net profit grew by 46.6% to approximately $10.0 million for the year ending December 31, 2024, compared to approximately $6.8 million for the year ending December 31, 2023[5] - The adjusted net profit for the year ending December 31, 2024, was approximately $26.9 million, compared to approximately $26.1 million for the previous year[5] - The company reported a total operating profit of $6.28 million for 2024, compared to a loss of $3.93 million in 2023[58] - The basic and diluted earnings per share for the year ended December 31, 2024, were both $0.07, up from $0.04 in 2023[59] - The company’s profit attributable to owners for the year ended December 31, 2024, was $12,114,000, an increase of 60.5% from $7,530,000 in 2023[86] Market Expansion - Revenue from markets outside of China surged by 290.4% to approximately $80.5 million, accounting for 30.0% of total revenue[4] - The number of completed cases in markets outside of China skyrocketed by 326.4% to approximately 140,700 cases, representing 39.1% of total completed cases[4] - The company plans to expand its global market presence, including establishing new manufacturing facilities in the U.S. and increasing support capabilities in Brazil[19] Product Development - The company launched the "KiD Max" and "KiD Anti-Cavity" product lines, expanding its pediatric product matrix to address oral health issues for children and adolescents[11] - Investment in research and development reached approximately $21.3 million in 2024, accounting for 7.9% of total revenue, with 241 patents and 22 software copyrights registered[12] - The company is focusing on innovation in key materials, product design, and software algorithms, with several research papers published in top international journals[14] Operational Efficiency - The company aims to enhance operational efficiency through further digitization of its systems and improve user experience in medical services[19] - Total costs increased by 27.4% from approximately $78.9 million for the year ended December 31, 2023, to approximately $100.6 million for the year ended December 31, 2024, primarily due to global business expansion[20] - Administrative expenses rose by 16.2% from approximately $39.8 million for the year ended December 31, 2023, to approximately $46.2 million for the year ended December 31, 2024, reflecting improved operational efficiency[23] Cash Flow and Assets - Cash and cash equivalents and term deposits totaled approximately $339.1 million as of December 31, 2024, down from approximately $379.7 million as of December 31, 2023[34] - Non-current assets increased to $186.44 million in 2024, up from $146.53 million in 2023, reflecting a growth of 27.19%[61] - The company reported a net cash outflow from investing activities of $138.83 million, similar to the $138.76 million in 2023[66] Shareholder Returns - The company plans to pay a special final dividend of HKD 0.38 per share for the year ending December 31, 2024[5] - The proposed special final dividend is HKD 0.38 per share, subject to approval at the annual general meeting[132] Corporate Governance - The company has adopted the corporate governance code and has complied with all applicable provisions during the reporting period[127] - The audit committee, consisting of three independent non-executive directors, has reviewed the group's annual performance for the year ending December 31, 2024, and recommended approval to the board[135] Employee and Management - Employee costs for the year ending December 31, 2024, are approximately USD 141.5 million[121] - Key management compensation totaled $8,588,000 for the year ending December 31, 2024, compared to $7,315,000 in 2023, reflecting an increase of 17.4%[114] - The company has 3,576 employees as of December 31, 2024[121]